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Silybin is a secondary metabolite isolated from the seeds of blessed milk thistle
(Silybum marianum) that has anti-inflammatory, antioxidative, antifibrotic, and antitumor
properties. Here, we showed that silybin protected against cisplatin-induced acute
kidney injury (AKI) by improving mitochondrial function through the regulation of sirtuin
3 (SIRT3) expression. Male SV129 and SIRT3 knockout (KO) mice were administered a
single intraperitoneal (i.p.) injection of cisplatin with or without treatment with silybin.
Moreover, cultured HK2 cells were used to evaluate mitochondrial morphology and
function. Our data suggested that silybin enhanced SIRT3 expression after cisplatin
administration both in vivo and in vitro. Silybin treatment improved mitochondrial function
and bioenergetics in wild-type, but not SIRT3-defective, cells and mice. Moreover, we
demonstrated that silybin markedly attenuated cisplatin-induced AKI and tubular cell
apoptosis and improved cell regeneration in a SIRT3-dependent manner. Collectively,
these results suggest that silybin is a pharmacological activator of SIRT3 capable
of protecting against cisplatin-induced tubular cell apoptosis and AKI by improving
mitochondrial function. Thus, silybin could serve as a potential clinical renoprotective
adjuvant treatment in cisplatin chemotherapy.
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INTRODUCTION
Cisplatin is one of the most efficient and widely used anticancer chemotherapy drugs in the clinic
for the treatment of bladder cancer, non-small cell lung cancer and other solid tumors (Siddik,
2003). However, its use is frequently limited by its adverse effects, such as neurotoxicity, bone
marrow suppression and nephrotoxicity. Among these effects, nephrotoxicity is the major limiting
factor for cisplatin therapy (Arany and Safirstein, 2003). The nephrotoxic effect of cisplatin is
cumulative and dose-dependent, and it often necessitates dose reduction or withdrawal (Pabla and
Dong, 2008).
It has been suggested that oxidative stress, a redox state imbalance, impaired energetic
metabolism, cell apoptosis and inflammation are likely associated with cisplatin-induced acute
kidney injury (AKI) (Miller et al., 2010). Recent studies have also demonstrated that mitochondrial
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dysfunction occurs in tubular epithelial cell injury and negatively
affects the recovery of renal function in cisplatin-induced AKI
(Zhan et al., 2013; Yang et al., 2014). Mitochondria are remarkably
dynamic organelles that constantly undergo fusion and fission
to maintain their integrity and quantity, and they play essential
roles in many aspects of biology in tubular epithelial cells
(Brooks et al., 2009; Palmer et al., 2011; Friedman and Nunnari,
2014). Sirtuin 3 (SIRT3) has been demonstrated to protect
against tubular injury in a cisplatin-induced AKI animal model
by preserving mitochondrial integrity, suggesting that elevating
renal SIRT3 expression to improve mitochondrial dynamics is
a potential strategy for improving the outcome of AKI (Morigi
et al., 2015). SIRT3 is an important member of the sirtuin family,
and it is the major acetylation enzyme located in mammalian
mitochondria (Michishita et al., 2005). Recent studies have
indicated that metabolic enzymes and oxidative phosphorylation
proteins that are potentially regulated via deacetylation by SIRT3
are important for mitochondrial energy production, metabolic
homeostasis, and cell survival and longevity (Ahn et al., 2008;
Verdin et al., 2010; Wu et al., 2013). In addition, SIRT3 increases
the activities of antioxidant enzymes and enhances the clearance
of mitochondrial reactive oxygen species (mtROS), thereby
reducing ROS-mediated cell damage and maintaining cellular
homeostasis (Kong et al., 2010; Bell and Guarente, 2011; Chen
et al., 2013). However, an effective strategy for the treatment
of tubular mitochondrial dysfunction in AKI remains to be
identified.
Silybin, a polyphenolic flavonoid, is widely used to treat
liver diseases due to its antioxidant, anti-inflammatory and
antifibrogenic properties and its ability to stimulate DNA and
RNA synthesis (Loguercio and Festi, 2011). The mechanism
underlying cisplatin renal toxicity has been proposed to be
the generation of free oxygen radicals and the inhibition
of DNA, RNA, and protein synthesis (Miller et al., 2010).
Therefore, we hypothesized that silybin would have an effect
on the kidney in cisplatin-induced AKI. In the present study,
we found that silybin improved mitochondrial function in
tubular epithelial cells and ameliorated the decline in renal
function in cisplatin-induced AKI. In addition, we found that
SIRT3 expression was significantly repressed in tubular epithelial
cells in cisplatin induced-AKI and that the administration of
silybin increased this expression, leading to improvements in
mitochondrial bioenergetics and kidney function. Taken together,
our results provide evidence of a direct interaction between
silybin and SIRT3 protein, suggesting that silybin therapy
can optimize the clinical outcomes of cisplatin induced-AKI
patients.
MATERIALS AND METHODS
Mice and AKI Model
Animal maintenance and experimental procedures were
conducted in accordance with protocols approved by the Animal
Care Committee of the Sun Yat-sen University. SIRT3 knockout
(KO) mice in an SV129 background were purchased from the
Jackson Laboratory, and wild-type (WT) control mice were
acquired from the Model Animal Research Center of Nanjing
University (China). Male mice weighing approximately 20–25 g
were administered cisplatin (20 mg/kg; Sigma–Aldrich, USA) or
a vehicle by a single i.p. injection as previous articles reported
(Gao et al., 2016; Suzuki et al., 2016). To investigate the effects
of silybin on cisplatin-induced AKI, the mice were pretreated
with 200 mg/kg silybin per day by intragastric administration for
7 days before and 3 days after cisplatin injection. The mice were
sacrificed under anesthesia 72 h after cisplatin administration,
and blood and kidney samples were collected and harvested for
biochemical and histopathologic examinations.
Cell Culture
HK2 cells were obtained from the American Type Culture
Collection (Manassas, VA, USA) and were grown in DMEM/F-12
(Gibco, USA) supplemented with 10% fetal bovine serum (FBS;
Gibco, USA), 100 U/ml penicillin and 100 µg/ml streptomycin
in a humidified atmosphere of 5% CO2/95% air at 37◦C. SIRT3
siRNA (Ribobio, China) was transfected into HK2 cells using
Lipofectamine 3000 reagent (Invitrogen, USA) according to the
manufacturer’s instructions. At 48 h after transfection, the cells
were stimulated with cisplatin (5 µmol/L) for an additional 24 h
in the presence or absence of silybin (50 µmol/L).
Histology and Immunohistochemistry
The kidney samples were fixed in 4% paraformaldehyde, stained
with periodic acid-Schiff (PAS) staining, and observed by light
microscopy. Cellular casts and necrosis were assessed in at
least 20 randomly chosen fields by microscopy (×400). For
SIRT3 immunohistochemical staining, 5-µm kidney sections
were incubated with anti-SIRT3 (Cell Signaling Technology,
USA), followed by incubation with the respective secondary
antibodies. The quantification of SIRT3-positive tubular regions
was performed by examining at least 20 fields (×200) for each
mouse.
Transmission Electron Microscopy
Fragments of cortical kidney tissues were fixed in 2.5%
glutaraldehyde in 0.1 M cacodylate buffer for at least 2 h.
Then, they were fixed in 1% osmium tetroxide, dehydrated
with ascending concentrations of ethanol, subjected to resin
penetration and embedded in epon. After solidification, the
tissues were cut into ultrathin sections and stained with uranyl
acetate, followed by staining with lead citrate; finally, they were
examined using a JEM-1400 transmission electron microscope
(Japan). The aspect ratio was calculated as previous published
methods (Ayanga et al., 2016).
Mitochondrial Function
Living HK2 cells were labeled with 300 nM MitoTracker Deep
Red (Invitrogen, USA) for 15 min at 37◦C. Mitochondrial
membrane potential was measured using the fluorescent
dye tetramethylrhodamine methyl ester (TMRM, 250 nM,
Invitrogen, USA) for 20 min. mtROS was detected by labeling
cells with MitoSOX Red (5 µM, Invitrogen) for 10 min. After
incubation, the cells were washed several times and examined
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under an inverted confocal microscope. The images were
analyzed by ImageJ for integrated density analysis. At least 100
cells were determined for each condition.
Real-time PCR for SIRT3 and
Quantification of mtDNA
Total RNA was extracted from HK2 cells and mouse renal
tissues using TRIzol reagent (Invitrogen, USA) according to the
manufacturer’s instructions. Then, the total RNA was reverse
transcribed using a PrimeScriptTM RT Reagent Kit with gDNA
Eraser (TaKaRa, Japan). SYBR R© Premix Ex TaqTM II (TaKaRa,
Japan) was used to amplify SIRT3 cDNA. SIRT3 gene expression
was normalized by β-actin expression.
Total DNA was extracted using a MiniBEST Universal
Genomic DNA Extraction Kit (TaKaRa, Japan). To determine
the mtDNA/gDNA ratio, qPCR was performed to amplify the
mitochondrial genome (mt16s) and nuclear genome (B2M), as
previously described (Bueno et al., 2015). The expression of
mtDNA was normalized by that of nuclear DNA using the
comparative cycle threshold (MM Ct) method.
The sequences of the primers used for PCR were as
follows: SIRT3 (mouse): forward, CACGTTTACAAACATG
AACC, reverse, CATGCTAGATTGCCCTAGT; β-actin (mouse):
forward, AGACCTTCAACACCCCAG, reverse, CACGATTT
CCCTCTCAGC; SIRT3 (human): forward, TGGCACCCA
GCACAATGAA, reverse, CTAAGTCATAGTCCGCCTAGAA
GCA; β-actin (human): forward, TGGCACCCAGCACAA
TGAA, reverse, CTAAGTCATAGTCCGCCTAGAAGCA; B2M
(human): forward, TGCTGTCTCCATGTTTGATGTATCT,
reverse, TCTCTGCTCCCCACCTCTAGGT; and mt16S
(human): forward, GCCTTCCCCCGTAAATGATA, reverse,
TTATGCGATTACCGGGCTCT.
ATP Production
Cellular ATP levels were determined using an Enhanced ATP
Assay Kit (Beyotime, China). Lysed cells were centrifuged for
5 min at 4◦C and 12,000 g, and the supernatant was collected.
Before ATP detection, detecting solution was added to a 96-well
plate and incubated at room temperature for 5 min. The
supernatant was then added to the plate, mixed quickly, and
read within 30 min. Total ATP levels were calculated from
the luminescence signals and were normalized by the protein
concentrations.
Apoptosis Analysis
For Annexin V FITC (BD Biosciences, San Diego, CA, USA)
labeling, HK2 cells were gathered by trypsinization, washed in
cold phosphate-buffered serum (PBS), and then incubated with
Annexin V FITC according to the manufacturer’s instructions.
Next, the cells were analyzed by flow cytometry.
Kidney apoptosis was measured using terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) staining (Roche Molecular Biochemicals, Germany).
The rate of apoptosis was calculated by examining at least 20
fields for each sample.
Proliferation Assay
At 72 h after cisplatin administration, the mice were administered
bromodeoxyuridine (BrdU; Sigma–Aldrich, USA) by i.p.
injection at a dose of 50 mg/kg body weight, and they were
sacrificed 2 h later. The proliferation of renal tubular cells
was identified by immunohistochemical analysis of BrdU and
proliferating cell nuclear antigen (PCNA). At least 10 fields
(×200) were examined for each mouse.
Immunoblotting
Cells were lysed in radioimmunoprecipitation assay (RIPA)
buffer (Thermo Fisher, USA) containing protease inhibitors
(Thermo Fisher, USA) before being scraped off and centrifuged
for 15 min at 4◦C and 12,000 g. Equal amounts of protein
were loaded onto 12% SDS-PAGE gels and transferred to
PVDF membranes (Millipore Corp., USA). The membranes
were blocked with 5% bovine serum albumin (BSA) in TBST
for 60 min and then incubated with a monoclonal rabbit
anti-SIRT3 antibody (1:1000, CST) or polyclonal rabbit anti-
cleaved caspase-3 antibody (1:1000, CST) with monoclonal
β-actin antibody-HRP (1:10000, Bioworld) overnight at 4◦C.
Subsequently, the membranes were incubated with a horseradish
peroxidase (HRP)-labeled goat anti-rabbit antibody (1:20000;
Bioworld Technology, USA) in TBST with 5% BSA for 60 min
at room temperature. The blots were visualized by enhanced
chemiluminescence (ECL; Millipore, USA), and the bands were
quantified using ImageJ software (National Institutes of Health,
Bethesda, MD, USA).
Statistical Analysis
All data were presented as the means ± SEM from three
independent experiments. A statistical comparison of the groups
was performed using the t-test or one-way analysis of variance
(ANOVA), followed by Bonferroni’s post hoc test. P < 0.05 was
considered to indicate statistical significance in all tests. SPSS 15.0
software was used for statistical analyses (SPSS Inc., USA).
RESULTS
Silybin Protects against
Cisplatin-induced AKI
To assess the effects of silybin on cisplatin-induced AKI, male
SV129 mice were i.p. injected with 20 mg/kg cisplatin to induce
AKI. After 3 days, the mice developed AKI, as demonstrated
by their elevated creatinine levels. To determine the role of
silybin in cisplatin-induced AKI, the mice were pretreated with
200 mg/kg silybin by intragastric administration for 7 days before
and 3 days after cisplatin injection. The blood urea nitrogen level
was significantly decreased in the silybin group compared with
the cisplatin group (Figure 1A).
Periodic acid-Schiff staining revealed apparently normal
kidney tubules in the vehicle group. However, the cisplatin group
exhibited severe kidney histological abnormalities, including
renal tubular epithelial cell edema and detachment. However,
the injury-promoting processes, including epithelial cell atrophy
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FIGURE 1 | Silybin protects against cisplatin-induced acute kidney injury (AKI). Male SV129 mice were treated with vehicle and cisplatin with or without
silybin (n = 6). (A) The graph shows the blood urea nitrogen (BUN) levels of mice 72 h after cisplatin injection. (B) Histological examination of periodic acid-Schiff
(PAS) staining in each group and (C) quantitation of tubular necrosis. Scale bar, 50 µm. ∗∗P < 0.01 vs. vehicle mice; #P < 0.05, ##P < 0.01 vs. mice treated with
cisplatin alone.
and necrosis, were significantly attenuated by pretreatment with
silybin (Figures 1B,C).
Taken together, these data indicated that silybin had a
protective effect on cisplatin-induced AKI compared with that
observed in the mice treated with cisplatin alone.
Effects of Silybin on Mitochondria in
Cisplatin-induced AKI
Three days after cisplatin administration, the cortices of the
mouse kidneys were observed using electron micrography to
evaluate the mitochondria. The control group had elongated
mitochondrial profiles; in contrast, the cisplatin group was found
to have small, fragmented, swollen and abnormal mitochondrial
profiles, while the silybin group had longer mitochondrial profiles
and reduced mitochondrial swelling than the cisplatin group
(Figure 2A). Consistent with the in vivo findings, the exposure
of HK2 cells to cisplatin resulted in small and fragmented
mitochondria, and treatment with silybin caused enlargement of
the mitochondria (Figure 2B).
Mitochondrial function in AKI was further investigated
in vitro in HK2 cells damaged by cisplatin. Several independent
parameters were assessed: mtROS were measured by MitoSOX
staining, membrane potential was measured by TMRM staining,
and mitochondrial function was evaluated by determining
the ATP level and mtDNA copy number. Cisplatin induced
excessive mtROS production (Figure 2C), massive mitochondrial
depolarization (Figure 2D) and reductions in ATP production
(Figure 2E) and the mtDNA copy number (Figure 2F) compared
with the controls. In contrast, treatment with silybin largely
reversed all of these changes. Taken together, these observations
indicated that silybin prevented cisplatin-induced mitochondrial
dysfunction in HK2 cells.
Silybin Increases SIRT3 Expression
A recent study indicated that SIRT3 is a critical mitochondrial
protein that protects the kidney against AKI (Perico et al., 2016).
PCR and western blotting revealed that SIRT3 expression was
clearly decreased in the cisplatin group, while pretreatment with
silybin markedly increased SIRT3 expression (Figures 3A,B).
Immunohistochemical staining also demonstrated that silybin
increased SIRT3 expression, especially in tubular epithelial cells,
compared with the cisplatin group (Figure 3C). Consistently,
the mRNA and protein expression of SIRT3 was reduced in
cisplatin-treated HK2 cells compared with control cells, while
treatment with silybin increased both types of SIRT3 expression
(Figures 3D,E). Thus, these data indicated that silybin was
capable of increasing mitochondrial SIRT3 expression.
Silybin Increases SIRT3 Expression to
Protect against Cisplatin-induced AKI
To determine whether silybin protects against cisplatin-induced
AKI via activation of SIRT3, we measured the effects of silybin in
SIRT3 KO mice. SIRT3 KO mice, along with their WT controls,
were injected with cisplatin, either alone or after pretreatment
with silybin. After 3 days, significant increases in blood urea
nitrogen levels and greater changes in tubular epithelial cells
were observed in both the silybin-treated and untreated SIRT3
KO cisplatin-treated mice compared with their WT littermates
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FIGURE 2 | Silybin improves mitochondria fitness. (A) Representative TEM micrographs of mouse renal tubular epithelial cell mitochondria from each group and
average aspect ratio. Scale bar, 1 µm. (B) Representative images showing the mitochondrial morphology of HK2 cells after staining with MitoTracker Deep Red and
quantitative analysis. Scale bar, 10 µm. (C,D) MitoSOX (C), TMRM (D), and quantitative analysis were used to examine mtROS and mitochondrial membrane
potential in HK2 cells. Scale bar, 10 µm. (E) ATP levels were quantified in HK2 cells. (F) Mitochondrial mass of HK2 cells was assessed using the mtDNA/nDNA
ratio. The data represent the means ± SEM. ∗P < 0.05, ∗∗P < 0.01 vs. vehicle mice or control cells; #P < 0.05 vs. mice or cells treated with cisplatin alone.
(Figures 4A,B). These results suggested that silybin was unable
to protect against cisplatin-induced AKI in the SIRT3 KO mice,
whereas it had a protective effect in the WT mice.
Ultrastructural analysis revealed an increased number of
swollen and fragmented mitochondria in the SIRT3 KO cisplatin-
treated mice compared with the WT cisplatin-treated mice.
However, silybin had no effect on elongating the mitochondrial
profiles in the SIRT3 KO mice (Figure 4C).
To assess mitochondrial function in cisplatin-induced AKI,
siRNA was used to downregulate SIRT3 expression. At 48 h
after SIRT3 siRNA (siSIRT3) transfection into HK2 cells, SIRT3
protein expression in the siSIRT3-transfected cells was decreased
by almost 90% compared with scrambled RNA-transfected cells
(Figure 4D). Next, the cells were treated with cisplatin in the
presence or absence of silybin after transfection with siSIRT3
or were left untreated after transfection with scrambled RNA.
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FIGURE 3 | Silybin can increase the expression of SIRT3 in cisplatin-induced AKI. (A) Real-time PCR analysis of whole-kidney expression of SIRT3 mRNA.
(B) Western blot and densitometric analysis of SIRT3 in the renal tissue of vehicle and cisplatin-treated mice after saline or silybin administration; n = 6 mice per
group. (C) Representative SIRT3 immunohistochemical staining of mouse kidney sections and semi-quantitative positive scoring of SIRT3 staining among different
groups. Scale bar, 50 µm. (D) Analysis of expression of SIRT3 transcripts in HK2 cells by RT-PCR. (E) Western blot and densitometric analysis of SIRT3 in control
and cisplatin-treated HK2 cells in the presence or absence of silybin. Each bar represents the means ± SEM for groups of six mice or three independent cell
experiments. ∗∗P < 0.01, ∗∗∗P < 0.001 vs. vehicle mice or control cells; #P < 0.05, ##P < 0.01 vs. mice or cells treated with cisplatin alone. Cis, cisplatin; cis+s,
cisplatin+silybin.
The results revealed that silybin could not reverse the changes
in mitochondrial morphology, mtROS level, mitochondrial
membrane potential (Figure 4E), ATP level (Figure 4F) or
mtDNA copy number (Figure 4G), which were all obviously
reversed in the silybin-treated WT cells.
In conclusion, these data suggested that the protective effects
of silybin in cisplatin-induced AKI involved the activation of
SIRT3.
Silybin Reduces Tubular Cell Apoptosis
and Improves Regeneration of these
Cells in Kidneys in Cisplatin-induced AKI
Apoptosis was examined by TUNEL staining in vivo
(Figures 5A,B) and by flow cytometry with Annexin V-FITC
and propidium iodide (PI) staining in vitro (Figures 5C,D).
The numbers of apoptotic cells in the cisplatin group, including
mice and HK2 cells, were significantly increased compared
with the control group, while many fewer apoptotic cells were
detected in the silybin group. Moreover, an increased number
of apoptotic cells was detected in the SIRT3-deficient cisplatin
group compared with the SIRT3-competent cisplatin group;
however, silybin pretreatment had no effect on this number in
the mice or HK2 cells.
Cleaved caspase-3 expression was also increased in the
cisplatin-treated mice compared with the controls for both the
WT and SIRT3 KO mice; however, its expression was much
higher in the SIRT3 KO cisplatin-treated mice than in the WT
cisplatin-treated mice (Figure 5E). Pretreatment with silybin
greatly decreased cleaved caspase-3 expression in the WT mice
but not in the SIRT3 KO mice (Figure 5F). These results further
support the SIRT3-mediated anti-apoptotic activity of silybin in
cisplatin-induced AKI.
Renal tubular epithelial cell regeneration was assessed by
examining BrdU uptake (Figures 6A,C) and PCNA staining
(Figures 6B,D). The results showed that few BrdU-positive
(BrdU+) and PCNA-positive (PCNA+) tubular cells were present
in the control group; however, cisplatin injection resulted in
substantial increases in the numbers of BrdU+ and PCNA+
cells in the WT mice but small or no increases in the SIRT3
KO mice. Notably, silybin provided strong protection against
cell death in the WT cisplatin-treated mice by promoting cell
proliferation, with greater numbers of BrdU+ and PCNA+ cells,
but this effect was not observed in the SIRT3 KO mice. These
observations indicate that cisplatin might promote abnormal
repair in AKI, and the small number of BrdU+ cells detected
in the SIRT3 KO cisplatin-treated mouse kidneys suggests that
SIRT3 deficiency likely inhibits cell regeneration by preventing
the entry of cells into the S phase. Accordingly, treatment with
silybin improved cell regeneration in the WT mice with cisplatin-
induced AKI, whereas it resulted in few proliferating cells in the
SIRT3 KO mice. Therefore, SIRT3 may act as a key regulator
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FIGURE 4 | Silybin protects against cisplatin-induced AKI by enhancing SIRT3 expression. (A) The graph shows the blood urea nitrogen (BUN) levels of
SIRT3 KO mice 72 h after cisplatin injection. (B) PAS staining and quantitation of tubular necrosis induced in the vehicle and cisplatin-injected kidneys of SIRT3 KO
mice treated with or without silybin. Scale bar, 50 µm. (C) Representative TEM and aspect ratio of renal tubular cell ultrastructure in kidney sections of the vehicle
and cisplatin-treated SIRT3 KO mice administered saline or silybin. Scale bar, 0.5 µm. (D) Western blot and densitometric analysis of SIRT3 protein expression
demonstrating the efficiency of transfected SIRT3 siRNA (siSIRT3) compared with scrambled RNA (SC). (E) Representative confocal images and quantitative analysis
exhibiting the mitochondrial morphology and function of HK2 cells either transfected with scrambled RNA then treated with control medium or transfected with
siSIRT3 then exposed to cisplatin alone or with silybin. Mitochondrial morphology was visualized by staining with MitoTracker Deep Red (top), and mtROS and
mitochondrial membrane potential were detected using MitoSOX (middle) and TMRM (bottom), respectively. Scale bar, 10 µm. (F) ATP levels and (G) mtDNA/nDNA
ratio were measured in HK2 cells either transfected with scrambled RNA then treated with control medium or transfected with siSIRT3 then treated with cisplatin
alone or with silybin. Results are presented as the means ± SEM for groups of six mice or three independent cell experiments. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001
vs. vehicle mice or control cells. KO, knockout; cis, cisplatin; cis+s, cisplatin+silybin; SC, scrambled RNA.
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FIGURE 5 | Silybin reduces tubular cell apoptosis via targeting SIRT3 in kidneys and cells with cisplatin-induced AKI. (A) Representative micrographs
showing a comparison of TUNEL staining in different groups between WT and KO mice. Scale bar, 10 µm. (B) Quantitative analysis of the number of TUNEL-positive
stained cells per field (×400). (C) Representative graphs showing the results of FACS analysis. HK2 cells transfected with scrambled RNA or with siSIRT3 and then
exposed to medium or cisplatin in the presence or absence of silybin were stained with annexin-V-FITC and PI to measure cell apoptosis. (D) Graph illustrating
percentages of cell apoptosis among different groups. (E,F) Western blot and densitometric analysis of cleaved caspase-3 protein expression in different groups
compared with WT and KO mice. The results are presented as the means ± SEM for groups of six mice or three independent cell experiments. ∗P < 0.05,
∗∗P < 0.01 vs. vehicle mice or control cells; #P < 0.05, ##P < 0.01 vs mice or cells treated with cisplatin alone; $P < 0.05 vs. WT mice or scrambled RNA cells
from the same group. WT, wild type; KO, knockout; cis, cisplatin; cis+s, cisplatin+silybin; SC, scrambled RNA.
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FIGURE 6 | Silybin treatment promotes tubular epithelial cell regeneration in cisplatin-induced AKI in WT mice, but not in SIRT3 KO mice. (A,C)
Immunohistochemical staining and quantitation of BrdU+ cells among different groups compared with WT and KO mice. (B,D) Immunohistochemical staining and
quantitation of PCNA+ cells among different groups compared with WT and KO mice. Scale bar, 10 µm. Each bar represents the means ± SEM for groups of six
mice. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. vehicle mice; #P < 0.05 vs mice treated with cisplatin alone; $$P < 0.01, $$$ P < 0.001 vs. WT mice from the same
group. WT, wild type; KO, knockout.
of the G1/S transition and in the pharmacologic promotion of
AKI repair, as silybin regulated SIRT3 expression to provide
strong protection against cisplatin-induced AKI by promoting
renal tubular epithelial cell proliferation.
DISCUSSION
The present study confirmed that SIRT3 plays an important
role in regulating mitochondrial function in renal tubular
epithelial cells. The results showed that a decrease in SIRT3
expression in renal tubular epithelial cells led to a reduction
in mitochondrial bioenergetics in the cisplatin-induced AKI
mice. Most importantly, the findings revealed that silybin, the
main component of silymarin that has been approved for
use in the treatment of liver injury, protected kidneys from
cisplatin-induced AKI. Administration of silybin before cisplatin
effectively protected mitochondrial function and reduced renal
tubular epithelial cell apoptosis. Silybin positively regulated
SIRT3 expression in tubular cells and ameliorated renal
dysfunction in the cisplatin-induced AKI model mice but had no
effect in the SIRT3 KO mice. Thus, enhancing SIRT3 expression
with silybin to improve mitochondrial function in tubular cells
is a potential strategy for improving the outcomes of renal injury
in AKI.
Experimental and clinical studies have shown that silybin
provides good protection against various liver diseases, such as
alcoholic liver disease, acute and chronic viral hepatitis and toxin-
induced liver diseases (Enjalbert et al., 2002; Jacobs et al., 2002;
Federico et al., 2006; Rambaldi et al., 2007). The antioxidant
and anti-inflammatory properties of silybin are considered to be
responsible for its hepatoprotective effects (Ligeret et al., 2008;
Trappoliere et al., 2009). Recent reports have demonstrated that
silybin is also associated with mitochondrial biogenesis and that
Frontiers in Pharmacology | www.frontiersin.org 9 April 2017 | Volume 8 | Article 178
fphar-08-00178 April 3, 2017 Time: 14:46 # 10
Li et al. Silybin Targets SIRT3
it prevents mtROS production by increasing the activities of
the superoxide dismutase and peroxidase enzymes in response
to liver injury (Detaille et al., 2008; Serviddio et al., 2014). In
addition, silybin promotes liver repair by membrane stabilization
and immunomodulatory and liver-regenerating mechanisms
(Polyak et al., 2007; Gharagozloo et al., 2008; Trouillas et al.,
2008). Moreover, it acts as an antifibrogenic agent by reducing the
TGF-β-induced synthesis of procollagen type I in human hepatic
stellate cells (Trappoliere et al., 2009). However, whether silybin
protects renal tubular epithelial cells in cisplatin-induced AKI
and the underlying critical role of mitochondria are unknown.
Several lines of evidence indicate that cisplatin nephrotoxicity
is mainly associated with mitochondria-generated ROS (Li et al.,
2011; Gao et al., 2013). The accumulation of cisplatin in renal
epithelial cells can lead to reduced ATP generation, a decline
in membrane potential and impaired mitochondrial respiration
(Santos et al., 2007; Maimaitiyiming et al., 2013). Our results
reinforce the importance of mitochondria as one of the key
components of cisplatin nephrotoxicity. We have provided
evidence that silybin ameliorates mitochondrial dysfunction in
tubular epithelial cells by modulating mitochondrial dynamics
and activity. Our data suggest that the administration of silybin
leads to a decrease in mtROS and increases in membrane
potential, ATP production and mtDNA copy number. Most
importantly, this study has unexpectedly revealed that SIRT3
is a mechanistic target of silybin in renal tubular cells in the
kidney, through which silybin regulates mitochondrial dynamics
and activity.
Sirtuin 3 is mainly located in mitochondria and exhibits
global mitochondrial lysine deacetylase activity (Lombard et al.,
2007). It participates in the regulation of energy metabolic
pathways (Guarente, 2014) through deacetylating various protein
in metabolic homeostasis (Martinez-Pastor and Mostoslavsky,
2012; Duan, 2013). In detail, recent studies have highlighted
roles of SIRT3 in the control of ATP production, fatty acid
oxidation, mitochondrial respiratory chain activity and oxidative
stress (Ahn et al., 2008; Bell and Guarente, 2011; Rahman et al.,
2014). Moreover, SIRT3 has been linked to the maintenance of
mitochondrial morphology through modulation of the fission
and fusion processes (Samant et al., 2014; Benigni et al., 2016). In
experimental cisplatin-induced AKI, decreased SIRT3 expression
is critical for the pathophysiology of tubular injury. SIRT3
prevents mitochondrial fragmentation, leading to decreased
tubular cell apoptosis and amelioration of renal damage caused
by cisplatin (Morigi et al., 2015). Consistent with these previous
findings, our results also indicated that cisplatin reduced SIRT3
expression in the kidney tubules and that SIRT3 deficiency
exacerbated AKI. Further, we found that silybin increased SIRT3
expression and ameliorated mitochondrial dysfunction in tubular
epithelial cells and kidney injury in AKI mice. However, silybin
had no beneficial effects in the SIRT3 KO AKI mice. Our results
also demonstrated that silybin reduced apoptosis and increased
the proliferation of renal tubular epithelial cells both in vitro and
in the mouse model. We have provided evidence that silybin
might protect the kidneys via the SIRT3 pathway by enhancing
renal tubular epithelial cell regeneration, which is crucial for the
recovery of renal structure and function after AKI.
Because the induction of apoptosis is the key means by
which cisplatin reduces tumor mass, it is unclear whether silybin
would counteract the therapeutic effect of cisplatin if it were
used as an adjunctive treatment. Fortunately, silybin has been
reported to enhance sensitivity to cisplatin therapy in esophageal
squamous cell carcinoma, colon adenocarcinoma, and prostate
carcinoma (Dhanalakshmi et al., 2003; Leon et al., 2015; Li
et al., 2016). However, the different behaviors of silybin in
normal and cancerous cells deserve consideration. In particular,
a review (Surai, 2015) noted that silybin has been shown to have
a protective effect against apoptosis in liver diseases, while it
causes apoptosis in cancerous cells. It seems that silybin produces
two different effects on normal and cancerous cells. Although
the anticancer properties of silybin are well established, these
divergent effects remain a mystery. Unraveling this mechanism
will represent a significant discovery in the fight against cancer.
Thus, the combination of silybin with cisplatin may provide
benefits that include not only protection of the kidneys but also
antitumor effects.
Collectively, these data suggest that silybin improves
mitochondrial function in renal tubular epithelial cells in
cisplatin-induced AKI through regulation of SIRT3 expression.
Although a large number of effective experimental treatments
have been identified for cisplatin-induced kidney injury, none of
these treatments are currently used in the clinic. Thus, enhancing
SIRT3 expression with silybin to improve mitochondrial function
in renal tubular epithelial cells may represent a novel strategy for
the prevention of cisplatin nephrotoxicity.
ETHICS STATEMENT
This study was carried out in accordance with the
recommendations of the Animal Care Committee of the Sun
Yat-sen University of guidelines, the Animal Care Committee
of the Sun Yat-sen University of committee. The protocol was
approved by the Animal Care Committee of the Sun Yat-sen
University of committee.
AUTHOR CONTRIBUTIONS
TL, YL, and ZY contributed substantially to the conception of the
work. YL, ZY, WL, and WH made the acquisition, analysis, or
interpretation of data for the work. TL, YL, and ZY drafted the
work for important intellectual content. TL, YL, and ZY made
the final approval of the version to be published. JR, XZ, and
ZY were took the agreement to be accountable for all aspects of
the work in ensuring that questions related to the accuracy or
integrity of any part of the work are appropriately investigated
and resolved.
ACKNOWLEDGMENTS
The study was supported by the National Natural Science
Foundation of China (Grant No. 81470954 and Grant No.
81070581).
Frontiers in Pharmacology | www.frontiersin.org 10 April 2017 | Volume 8 | Article 178
fphar-08-00178 April 3, 2017 Time: 14:46 # 11
Li et al. Silybin Targets SIRT3
REFERENCES
Ahn, B. H., Kim, H. S., Song, S., Lee, I. H., Liu, J., Vassilopoulos, A., et al.
(2008). A role for the mitochondrial deacetylase SIRT3 in regulating energy
homeostasis. Proc. Natl. Acad. Sci. U.S.A. 105, 14447–14452. doi: 10.1073/pnas.
0803790105
Arany, I., and Safirstein, R. L. (2003). Cisplatin nephrotoxicity. Semin. Nephrol. 23,
460–464.
Ayanga, B. A., Badal, S. S., Wang, Y., Galvan, D. L., Chang, B. H., Schumacker, P. T.,
et al. (2016). Dynamin-related protein 1 deficiency improves mitochondrial
fitness and protects against progression of diabetic nephropathy. J. Am. Soc.
Nephrol. 27, 2733–2747. doi: 10.1681/ASN.2015101096
Bell, E. L., and Guarente, L. (2011). The SIRT3 divining rod points to oxidative
stress. Mol. Cell 42, 561–568. doi: 10.1016/j.molcel.2011.05.008
Benigni, A., Perico, L., and Macconi, D. (2016). Mitochondrial dynamics is linked
to longevity and protects from end-organ injury: the emerging role of sirtuin 3.
Antioxid. Redox Signal. 25, 185–199. doi: 10.1089/ars.2016.6682
Brooks, C., Wei, Q., Cho, S. G., and Dong, Z. (2009). Regulation of mitochondrial
dynamics in acute kidney injury in cell culture and rodent models. J. Clin. Invest.
119, 1275–1285. doi: 10.1172/JCI37829
Bueno, M., Lai, Y. C., Romero, Y., Brands, J., St Croix, C. M., Kamga, C., et al.
(2015). PINK1 deficiency impairs mitochondrial homeostasis and promotes
lung fibrosis. J. Clin. Invest. 125, 521–538. doi: 10.1172/JCI74942
Chen, C. J., Fu, Y. C., Yu, W., and Wang, W. (2013). SIRT3 protects cardiomyocytes
from oxidative stress-mediated cell death by activating NF-kappaB. Biochem.
Biophys. Res. Commun. 430, 798–803. doi: 10.1016/j.bbrc.2012.11.066
Detaille, D., Sanchez, C., Sanz, N., Lopez-Novoa, J. M., Leverve, X., and El-Mir,
M. Y. (2008). Interrelation between the inhibition of glycolytic flux by silibinin
and the lowering of mitochondrial ROS production in perifused rat hepatocytes.
Life Sci. 82, 1070–1076. doi: 10.1016/j.lfs.2008.03.007
Dhanalakshmi, S., Agarwal, P., Glode, L. M., and Agarwal, R. (2003). Silibinin
sensitizes human prostate carcinoma DU145 cells to cisplatin-and carboplatin-
induced growth inhibition and apoptotic death. Int. J. Cancer 106, 699–705.
doi: 10.1002/ijc.11299
Duan, W. (2013). Sirtuins: from metabolic regulation to brain aging. Front. Aging
Neurosci. 5:36. doi: 10.3389/fnagi.2013.00036
Enjalbert, F., Rapior, S., Nouguier-Soule, J., Guillon, S., Amouroux, N., and
Cabot, C. (2002). Treatment of amatoxin poisoning: 20-year retrospective
analysis. J. Toxicol. Clin. Toxicol. 40, 715–757.
Federico, A., Trappoliere, M., Tuccillo, C., de Sio, I., Di Leva, A., Del Vecchio
Blanco, C., et al. (2006). A new silybin-vitamin E-phospholipid complex
improves insulin resistance and liver damage in patients with non-alcoholic
fatty liver disease: preliminary observations. Gut 55, 901–902. doi: 10.1136/gut.
2006.091967
Friedman, J. R., and Nunnari, J. (2014). Mitochondrial form and function. Nature
505, 335–343. doi: 10.1038/nature12985
Gao, L., Wu, W. F., Dong, L., Ren, G. L., Li, H. D., Yang, Q., et al. (2016).
Protocatechuic aldehyde attenuates cisplatin-induced acute kidney injury by
suppressing nox-mediated oxidative stress and renal inflammation. Front.
Pharmacol. 7:479. doi: 10.3389/fphar.2016.00479
Gao, S., Chen, T., Choi, M. Y., Liang, Y., Xue, J., and Wong, Y. S. (2013).
Cyanidin reverses cisplatin-induced apoptosis in HK-2 proximal tubular cells
through inhibition of ROS-mediated DNA damage and modulation of the
ERK and AKT pathways. Cancer Lett. 333, 36–46. doi: 10.1016/j.canlet.2012.
12.029
Gharagozloo, M., Khoshdel, Z., and Amirghofran, Z. (2008). The effect of an
iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a
comparison with desferrioxamine. Eur. J. Pharmacol. 589, 1–7. doi: 10.1016/j.
ejphar.2008.03.059
Guarente, L. (2014). The many faces of sirtuins: sirtuins and the warburg effect.
Nat. Med. 20, 24–25. doi: 10.1038/nm.3438
Jacobs, B. P., Dennehy, C., Ramirez, G., Sapp, J., and Lawrence, V. A. (2002). Milk
thistle for the treatment of liver disease: a systematic review and meta-analysis.
Am. J. Med. 113, 506–515.
Kong, X., Wang, R., Xue, Y., Liu, X., Zhang, H., Chen, Y., et al. (2010). Sirtuin 3, a
new target of PGC-1alpha, plays an important role in the suppression of ROS
and mitochondrial biogenesis. PLoS ONE 5:e11707. doi: 10.1371/journal.pone.
0011707
Leon, I. E., Cadavid-Vargas, J. F., Tiscornia, I., Porro, V., Castelli, S., Katkar, P., et al.
(2015). Oxidovanadium (IV) complexes with chrysin and silibinin: anticancer
activity and mechanisms of action in a human colon adenocarcinoma model.
J. Biol. Inorg. Chem. 20, 1175–1191. doi: 10.1007/s00775-015-1298-7
Li, J., Li, B., Xu, W. W., Chan, K. W., Guan, X. Y., Qin, Y. R., et al. (2016).
Role of AMPK signaling in mediating the anticancer effects of silibinin in
esophageal squamous cell carcinoma. Expert Opin. Ther. Targets 20, 7–18.
doi: 10.1517/14728222.2016.1121236
Li, Y., Li, X., Wong, Y. S., Chen, T., Zhang, H., Liu, C., et al. (2011). The reversal
of cisplatin-induced nephrotoxicity by selenium nanoparticles functionalized
with 11-mercapto-1-undecanol by inhibition of ROS-mediated apoptosis.
Biomaterials 32, 9068–9076. doi: 10.1016/j.biomaterials.2011.08.001
Ligeret, H., Brault, A., Vallerand, D., Haddad, Y., and Haddad, P. S.
(2008). Antioxidant and mitochondrial protective effects of silibinin in cold
preservation-warm reperfusion liver injury. J. Ethnopharmacol. 115, 507–514.
doi: 10.1016/j.jep.2007.10.024
Loguercio, C., and Festi, D. (2011). Silybin and the liver: from basic research to
clinical practice. World J. Gastroenterol. 17, 2288–2301. doi: 10.3748/wjg.v17.
i18.2288
Lombard, D. B., Alt, F. W., Cheng, H. L., Bunkenborg, J., Streeper, R. S.,
Mostoslavsky, R., et al. (2007). Mammalian Sir2 homolog SIRT3 regulates global
mitochondrial lysine acetylation. Mol. Cell. Biol. 27, 8807–8814. doi: 10.1128/
MCB.01636-1637
Maimaitiyiming, H., Li, Y., Cui, W., Tong, X., Norman, H., Qi, X., et al. (2013).
Increasing cGMP-dependent protein kinase I activity attenuates cisplatin-
induced kidney injury through protection of mitochondria function. Am. J.
Physiol. Renal Physiol. 305, F881–F890. doi: 10.1152/ajprenal.00192.2013
Martinez-Pastor, B., and Mostoslavsky, R. (2012). Sirtuins, metabolism, and cancer.
Front. Pharmacol. 3:22. doi: 10.3389/fphar.2012.00022
Michishita, E., Park, J. Y., Burneskis, J. M., Barrett, J. C., and Horikawa, I. (2005).
Evolutionarily conserved and nonconserved cellular localizations and functions
of human SIRT proteins. Mol. Biol. Cell 16, 4623–4635. doi: 10.1091/mbc.E05-
01-0033
Miller, R. P., Tadagavadi, R. K., Ramesh, G., and Reeves, W. B. (2010). Mechanisms
of Cisplatin nephrotoxicity. Toxins 2, 2490–2518. doi: 10.3390/toxins2112490
Morigi, M., Perico, L., Rota, C., Longaretti, L., Conti, S., Rottoli, D., et al.
(2015). Sirtuin 3-dependent mitochondrial dynamic improvements protect
against acute kidney injury. J. Clin. Invest. 125, 715–726. doi: 10.1172/JCI
77632
Pabla, N., and Dong, Z. (2008). Cisplatin nephrotoxicity: mechanisms and
renoprotective strategies. Kidney Int. 73, 994–1007. doi: 10.1038/sj.ki.5002786
Palmer, C. S., Osellame, L. D., Stojanovski, D., and Ryan, M. T. (2011). The
regulation of mitochondrial morphology: intricate mechanisms and dynamic
machinery. Cell. Signal. 23, 1534–1545. doi: 10.1016/j.cellsig.2011.05.021
Perico, L., Morigi, M., and Benigni, A. (2016). Mitochondrial sirtuin 3 and renal
diseases. Nephron 134, 14–19. doi: 10.1159/000444370
Polyak, S. J., Morishima, C., Shuhart, M. C., Wang, C. C., Liu, Y., and Lee, D. Y.
(2007). Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB
signaling, and HCV infection by standardized Silymarin. Gastroenterology 132,
1925–1936. doi: 10.1053/j.gastro.2007.02.038
Rahman, M., Nirala, N. K., Singh, A., Zhu, L. J., Taguchi, K., Bamba, T., et al.
(2014). Drosophila Sirt2/mammalian SIRT3 deacetylates ATP synthase beta
and regulates complex V activity. J. Cell Biol. 206, 289–305. doi: 10.1083/jcb.
201404118
Rambaldi, A., Jacobs, B. P., and Gluud, C. (2007). Milk thistle for alcoholic
and/or hepatitis B or C virus liver diseases. Cochrane Database Syst. Rev.
2007:CD003620. doi: 10.1002/14651858.CD003620.pub3
Samant, S. A., Zhang, H. J., Hong, Z., Pillai, V. B., Sundaresan, N. R., Wolfgeher, D.,
et al. (2014). SIRT3 deacetylates and activates OPA1 to regulate mitochondrial
dynamics during stress. Mol. Cell. Biol. 34, 807–819. doi: 10.1128/MCB.01483-
1413
Santos, N. A., Catao, C. S., Martins, N. M., Curti, C., Bianchi, M. L., and
Santos, A. C. (2007). Cisplatin-induced nephrotoxicity is associated with
oxidative stress, redox state unbalance, impairment of energetic metabolism
and apoptosis in rat kidney mitochondria. Arch. Toxicol. 81, 495–504.
doi: 10.1007/s00204-006-0173-172
Serviddio, G., Bellanti, F., Stanca, E., Lunetti, P., Blonda, M., Tamborra, R., et al.
(2014). Silybin exerts antioxidant effects and induces mitochondrial biogenesis
Frontiers in Pharmacology | www.frontiersin.org 11 April 2017 | Volume 8 | Article 178
fphar-08-00178 April 3, 2017 Time: 14:46 # 12
Li et al. Silybin Targets SIRT3
in liver of rat with secondary biliary cirrhosis. Free Radic. Biol. Med. 73,
117–126. doi: 10.1016/j.freeradbiomed.2014.05.002
Siddik, Z. H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of
resistance. Oncogene 22, 7265–7279. doi: 10.1038/sj.onc.1206933
Surai, P. F. (2015). Silymarin as a natural antioxidant: an overview of the
current evidence and perspectives. Antioxidants 4, 204–247. doi: 10.3390/
antiox4010204
Suzuki, T., Yamaguchi, H., Kikusato, M., Hashizume, O., Nagatoishi, S., Matsuo, A.,
et al. (2016). Mitochonic acid 5 binds mitochondria and ameliorates renal
tubular and cardiac myocyte damage. J. Am. Soc. Nephrol. 27, 1925–1932.
doi: 10.1681/ASN.2015060623
Trappoliere, M., Caligiuri, A., Schmid, M., Bertolani, C., Failli, P., Vizzutti, F., et al.
(2009). Silybin, a component of sylimarin, exerts anti-inflammatory and anti-
fibrogenic effects on human hepatic stellate cells. J. Hepatol. 50, 1102–1111.
doi: 10.1016/j.jhep.2009.02.023
Trouillas, P., Marsal, P., Svobodova, A., Vostalova, J., Gazak, R., Hrbac, J., et al.
(2008). Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin
flavonolignans: a joint experimental and theoretical study. J. Phys. Chem. A 112,
1054–1063. doi: 10.1021/jp075814h
Verdin, E., Hirschey, M. D., Finley, L. W., and Haigis, M. C. (2010). Sirtuin
regulation of mitochondria: energy production, apoptosis, and signaling.
Trends Biochem. Sci. 35, 669–675. doi: 10.1016/j.tibs.2010.07.003
Wu, Y. T., Lee, H. C., Liao, C. C., and Wei, Y. H. (2013). Regulation of
mitochondrial F(o)F(1)ATPase activity by Sirt3-catalyzed deacetylation and its
deficiency in human cells harboring 4977bp deletion of mitochondrial DNA.
Biochim. Biophys. Acta 1832, 216–227. doi: 10.1016/j.bbadis.2012.10.002
Yang, Y., Liu, H., Liu, F., and Dong, Z. (2014). Mitochondrial dysregulation
and protection in cisplatin nephrotoxicity. Arch. Toxicol. 88, 1249–1256.
doi: 10.1007/s00204-014-1239-1231
Zhan, M., Brooks, C., Liu, F., Sun, L., and Dong, Z. (2013). Mitochondrial
dynamics: regulatory mechanisms and emerging role in renal pathophysiology.
Kidney Int. 83, 568–581. doi: 10.1038/ki.2012.441
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Li, Ye, Lai, Rao, Huang, Zhang, Yao and Lou. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 12 April 2017 | Volume 8 | Article 178
